Quanome Technologies (QNME) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$5.9M

Revenue (quarter)

$742,294.00

Revenue growth (year over year)

−63.74%

Gross profit (trailing twelve months)

$3.3M

Gross margin

56.66%

Net income (trailing twelve months)

−$9.5M

Net income (quarter)

−$6.7M

Net income growth (year over year)

−648.57%

Net margin

−162.10%

Return on equity

−192.54%

EPS (trailing twelve months)

−$0.36

Book value per share

$0.20

P/E (trailing twelve months)

—

Price to book

2.98

Debt to assets

39.89%

Payout ratio

—

Dividend yield

—

Company profile

Quanome Technologies Inc operates in the midstream segment of the pharmaceutical industrial ecosystem, operating between upstream pharmaceutical manufacturers and downstream medical end customers. It sources products from multiple manufacturers and suppliers, and distribute them to hospitals, pharmaceutical distributors and other healthcare providers. Its principal product categories include infusion products, foods for special medical purposes, and specialty pharmaceuticals. It operates in one reportable segment serves its customers by providing pharmaceutical products in China. The company generates a substantial percentage of its revenue from selling pharmaceutical products on a direct basis.

• Is Quanome Technologies (QNME) profitable?

  No. Quanome Technologies reported a net loss of $9.5M over the trailing twelve months.

• How much revenue does Quanome Technologies (QNME) make?

  Quanome Technologies generated $5.9M in revenue over the trailing twelve months, down 63.74% year over year.

• How do I buy stock in Quanome Technologies (QNME)?

  QNME trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.